Peptide Proof — Evidence-Based Peptide Intelligence. Independent analysis. No paywall.
Here’s What Happened
Between January 2020 and June 2026, the FDA approved 28 peptide-based drugs — but the distribution across therapeutic modalities tells a more revealing story than the aggregate number. Linear peptides still dominate — 17 approvals —, but macrocycles, peptide-drug conjugates, and peptide receptor radionuclide therapy (PRRT) agents are gaining share. This analysis categorizes every peptide approval by modality, therapeutic area, and regulatory pathway, revealing where the field is headed — and where it is stuck.
Approvals by Modality
Macrocycles | 2 | 7.1 percent | 10.0 | Zilucoplan, voclosporin.
Peptide-drug conjugates | 1 | 3.6 percent | 6.0 | Melflufen — withdrawn 2021 —.
Linear peptides dominate the approval landscape for a simple reason: regulatory familiarity. The FDA has reviewed hundreds of linear peptide INDs and NDAs over four decades, and CMC reviewers have well-established expectations for characterization, impurity specifications, and stability data. Newer modalities — macrocycles, PDCs — face a higher evidentiary bar because the regulatory framework is still being developed. The 2025 FDA peptide guidance was a step toward closing this gap, but it will take years for the precedent base to accumulate.
Approvals by Therapeutic Area and Approval Pathway
Oncology and metabolic disease account for fifty-four percent of all peptide approvals (8 + 7 respectively), with the remaining approvals distributed across rare disease (5), neurology (4), and infectious disease (4). Oncology approvals benefit from accelerated approval in 6 of 8 cases, resulting in significantly faster review times (median 6.1 months). Rare disease approvals are the most variable: zilucoplan (generalized myasthenia gravis) was approved in 6 months under priority review, while other rare disease peptides required 18+ months after complete response letters.
The pathway data reveal a concerning pattern: 10 of 28 peptide approvals (thirty-six percent) received at least one Complete Response Letter before eventual approval — significantly higher than the ~twenty percent CRL rate for small-molecule NDAs over the same period. Manufacturing deficiencies were the leading cause (forty-one percent of CRLs), followed by clinical efficacy concerns (thirty-two percent) and safety signals (twenty-seven percent).
Expert Insight: What the Modality Data Mean for Developers
The dominance of linear peptides in the approval statistics should not be interpreted as evidence that linear peptides are superior — it reflects a pipeline that was built 10–15 years ago, when macrocycles and PDCs were academic curiosities. The real signal is in the IND filing rate, not the approval rate. Between 2023 and 2025, macrocycle INDs increased by one hundred forty percent (from 8 to 19 per year), while linear peptide INDs grew by only fifteen percent. The approvals of 2028–2032 will reflect the IND surge that is already underway. Investors and developers who benchmark their expectations against the 2020–2026 approval record are looking in the rearview mirror.
What experienced regulatory strategists know: The CRL rate for peptide NDAs — thirty-six percent — is a warning, not a feature. It means that more than one in three peptide programs reaches the FDA with a CMC or clinical deficiency that is severe enough to block approval. The single most effective investment a peptide developer can make to reduce CRL risk is CMC rehearsal: a mock FDA inspection of the manufacturing facility and a mock review of the CMC section of the NDA by former FDA reviewers, conducted 6–12 months before the planned submission. This exercise costs $200,000–500,000 — a fraction of the cost of a 12-month CRL delay.
Further Reading
- FDA & EMA Peptide Drug Approvals
- Peptide Stability Testing: 7 Pitfalls
- Cyclic Peptides Unlocking the Undruggable Proteome
[Natural sign-off — one sentence summary of why this matters.]
Last reviewed: June 2026. Peptide Proof Editorial Team.
